Deutsche Bank AG grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 15.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 277,853 shares of the company's stock after acquiring an additional 37,907 shares during the period. Deutsche Bank AG owned about 0.19% of Denali Therapeutics worth $5,663,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in DNLI. Sterling Capital Management LLC raised its stake in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after acquiring an additional 1,516 shares during the period. PNC Financial Services Group Inc. increased its stake in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares during the period. KBC Group NV increased its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after buying an additional 2,731 shares during the period. AlphaQuest LLC increased its stake in Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after buying an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. increased its stake in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after buying an additional 2,436 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.
Denali Therapeutics Price Performance
Shares of NASDAQ:DNLI traded down $0.03 during trading on Thursday, reaching $13.66. 1,028,555 shares of the company's stock traded hands, compared to its average volume of 1,098,504. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a 50 day moving average of $14.02 and a 200-day moving average of $19.38. The stock has a market capitalization of $1.98 billion, a P/E ratio of -4.95 and a beta of 1.49.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter in the previous year, the business earned ($0.68) EPS. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. HC Wainwright dropped their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Robert W. Baird dropped their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Finally, Wedbush dropped their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $33.71.
View Our Latest Stock Report on DNLI
Denali Therapeutics Company Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Recommended Stories
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
